The intrathecally administered kappa-2 opioid agonist GR89696 and interleukin-10 attenuate bone cancer-induced pain through synergistic interaction.

Kim, Woong Mo

The intrathecally administered kappa-2 opioid agonist GR89696 and interleukin-10 attenuate bone cancer-induced pain through synergistic interaction. [electronic resource] - Anesthesia and analgesia Oct 2011 - 934-40 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1526-7598

10.1213/ANE.0b013e318227824e doi


Analgesics, Opioid--administration & dosage
Animals
Anti-Inflammatory Agents--administration & dosage
Behavior, Animal--drug effects
Bone Neoplasms--complications
Breast Neoplasms--pathology
Cell Line, Tumor
Disease Models, Animal
Dose-Response Relationship, Drug
Drug Synergism
Female
Injections, Spinal
Interleukin-10--administration & dosage
Pain--drug therapy
Pain Measurement
Pain Threshold--drug effects
Piperazines--administration & dosage
Pyrrolidines--administration & dosage
Rats
Rats, Sprague-Dawley
Receptors, Opioid, kappa--agonists
Tibia--pathology
Time Factors